Latest Regulatory News

Brazilian Critical Minerals has achieved a significant milestone in its Ema project by successfully demonstrating magnesium sulphate migration and pH reduction in field trials, validating its in-situ recovery method for rare earth elements.

AdAlta Limited has successfully placed the remaining shortfall in its renounceable rights issue, raising a total of $1.3 million to advance its cellular immunotherapy pipeline. The company also addressed an administrative breach involving director share allocations, ensuring compliance with ASX rules.

Macarthur Minerals has relaunched a renounceable rights issue to raise nearly A$2 million, fully underwritten by Gold Valley, aiming to fund its Lake Giles Iron Project and strengthen its balance sheet.

Macarthur Minerals Limited has issued a replacement prospectus for a renounceable entitlement offer aiming to raise approximately AUD 2 million, fully underwritten by Gold Valley Yilgarn Pty Ltd. The offer includes free attaching options and supports the company’s exploration and operational funding needs.

Western Gold Resources has voluntarily suspended its shares from trading as it prepares to disclose details of a significant agreement and respond to an ASX price query.

Dimerix has reached a key milestone by dosing 200 adult patients in its Phase 3 ACTION3 trial for FSGS, progressing steadily toward full recruitment expected in late 2025.

Heavy Rare Earths Limited has validated a significant uranium anomaly at its Perenjori project in Western Australia, with soil assays reaching up to 116 ppm uranium. The company is preparing to drill and test this promising target, which compares favorably with established regional uranium deposits.

Santana Minerals has announced a delay in submitting its Fast Track Approvals Application due to pending ecological consultant reports, missing the previously set June 30 deadline. The company remains optimistic about finalising the reports soon and prioritising the submission.

Syntara Limited reports encouraging interim Phase 2 data for its drug SNT-5505 combined with ruxolitinib, demonstrating significant symptom relief and spleen volume reduction in myelofibrosis patients. The company plans to engage the FDA soon to discuss pivotal trial design.

Syntara Limited is set to reveal fresh interim results from its Phase 2 trial of SNT-5505, targeting myelofibrosis, during an investor webinar ahead of a major European hematology conference.

Tivan Limited has made significant progress on a revised access road for its Speewah Fluorite Project, balancing infrastructure needs with cultural heritage preservation. The company also secured key native title agreements and regulatory approvals supporting its feasibility study and joint venture with Sumitomo Corporation.

Vulcan Energy has received building permits for its 30MW geothermal renewable energy plant in Germany, advancing its goal of carbon-neutral lithium production for Europe’s battery industry.